Skip to Main Content

KMAP BULLETIN: Preferred Drug List Update – May 2026

Date: 04/28/26

KMAP GENERAL BULLETIN 26070 (PDF)

Effective with dates of service on or after May 1, 2026, the following medications will be Non-Preferred:

  • Arynta™ (lisdexamfetamine)
  • Atmeksi® (methocarbamol)
  • Aukelso™ (denosumab‑kyqq)
  • Bosaysa™ (denosumab‑kyqq)
  • Metoprolol tartrate 12.5 mg
  • Nucynta® (tapentadol hydrochloride)
  • Nucynta® ER (tapentadol hydrochloride)
  • Ontralfy™ (tizanidine)
  • Redemplo® (Plozasiran)
  • Sdamlo™ (amlodipine)
  • Sodium sulfacetamide–sulfur (Labeler 73352)
  • Zybic™ (meloxicam)


Effective with dates of service on or after May 1, 2026, the following medications will be Preferred:

  • Wegovy® (semaglutide) HD
  • Tryngolza™ (Olezarsen)


Effective with dates of service on or after May 1, 2026, the following medications will be removed from Preferred Drug List (PDL): 

  • Kalydeco®
  • Orkambi®
  • Symdeko®


Note: The effective date of the policy is May 1, 2026. The implementation of State policy by the KanCare Managed Care Organizations (MCOs) may vary from the date noted in the Kansas Medical Assistance Program (KMAP) bulletins. The KanCare Open Claims Resolution Log on the KMAP Bulletins page documents the MCO system status for policy implementation and any associated reprocessing completion dates once the policy is implemented.